Betting on Safety: The IoM Report's Impact on Wall Street
This article was originally published in RPM Report
Executive Summary
The Institute of Medicine is recommending big changes in how FDA deals with drug safety issues. Is it possible that will be good news on Wall Street? Drug safety expert and managing director of investment company Symphony Capital, Alastair Wood, weighs in.
You may also be interested in...
IoM's Sheila Burke on the Drug Safety Climate
The chair of the Institute of Medicine drug safety committee, Sheila Burke, agreed to an interview with The RPM Report on about issues related to the Food & Drug Administration's approval process and the debate on Capitol Hill over proposed legislation. Here are excerpts of the conversation.
Everything but the Kitchen Sink: IoM Drug Safety Report Gives FDA Options
The Institute of Medicine's drug safety committee came down hard on FDA's efforts to make sure drugs they approve are safe and effective. But FDA dodged a bullet based on what isn't in the report.
Moving Beyond Aduhelm: Cell/Gene Therapy May Be ‘Poster Child’ For What Comes Next
Former FDA principal deputy commissioner Amy Abernethy says cell and gene therapy is an area primed for improved ‘parallel conversation’ between FDA and CMS on data requirements.